 Sulfonamides
"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 1 | 1 | 2 | | 1991 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1994 | 1 | 1 | 2 | | 1997 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 2000 | 2 | 2 | 4 | | 2001 | 1 | 0 | 1 | | 2002 | 5 | 0 | 5 | | 2003 | 4 | 1 | 5 | | 2004 | 5 | 1 | 6 | | 2005 | 5 | 2 | 7 | | 2006 | 8 | 7 | 15 | | 2007 | 4 | 4 | 8 | | 2008 | 8 | 5 | 13 | | 2009 | 5 | 3 | 8 | | 2010 | 6 | 3 | 9 | | 2011 | 12 | 4 | 16 | | 2012 | 7 | 4 | 11 | | 2013 | 9 | 6 | 15 | | 2014 | 13 | 7 | 20 | | 2015 | 9 | 7 | 16 | | 2016 | 6 | 6 | 12 | | 2017 | 8 | 5 | 13 | | 2018 | 9 | 9 | 18 | | 2019 | 9 | 6 | 15 | | 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Weiss AR, Chen YL, Scharschmidt TJ, Chi YY, Tian J, Black JO, Davis JL, Fanburg-Smith JC, Zambrano E, Anderson J, Arens R, Binitie O, Choy E, Davis JW, Hayes-Jordan A, Kao SC, Kayton ML, Kessel S, Lim R, Meyer WH, Million L, Okuno SH, Ostrenga A, Parisi MT, Pryma DA, Randall RL, Rosen MA, Schlapkohl M, Shulkin BL, Smith EA, Sorger JI, Terezakis S, Hawkins DS, Spunt SL, Wang D. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2020 08; 21(8):1110-1122.
-
Gutman JA, Pollyea DA. Hypomethylating agents with venetoclax: have we discovered the holy grail? Curr Opin Hematol. 2020 Mar; 27(2):76-80.
-
Levy AE, Biswas M, Weber R, Tarakji K, Chung M, Noseworthy PA, Newton-Cheh C, Rosenberg MA. Applications of machine learning in decision analysis for dose management for dofetilide. PLoS One. 2019; 14(12):e0227324.
-
Sinha J, Dobson A, Bankhar O, Podgórski M, Shah PK, Zajdowicz SLW, Alotaibi A, Stansbury JW, Bowman CN. Vinyl sulfonamide based thermosetting composites via thiol-Michael polymerization. Dent Mater. 2020 02; 36(2):249-256.
-
Kiser JJ. Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest? Clin Infect Dis. 2019 10 30; 69(10):1665-1666.
-
Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019 10 22; 3(20):2911-2919.
-
Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019 12; 33(12):2795-2804.
-
Jordan CT. Can we selectively target AML stem cells? Best Pract Res Clin Haematol. 2019 12; 32(4):101100.
-
Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol. 2019 11; 85(11):2499-2511.
-
Pollyea DA. Acute myeloid leukemia drug development in the post-venetoclax era. Am J Hematol. 2019 09; 94(9):959-962.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|